Session Name: Concurrent Session: Pathways of Clinical Rejection
Session Type: Concurrent Session
Date: Sunday, April 30, 2017
Session Time: 4:30pm-6:00pm
Presentation Time: 5:18pm-5:30pm
Current thinking holds that costimulation-blockade resistant graft rejection may be mediated by CD28null T cells. To further investigate this possibility, we performed a retrospective immunophenotypic analysis of adult renal transplant recipients who experienced acute rejection on belatacept treatment compared to those that did not. We identified a subset of CD28null CD4+ TEM that are elevated at baseline in patients that did not go on to experience acute rejection (p<0.0001). Our data demonstrate that this CD28null CD4+ TEM population contained fewer IL-2 producing cells and showed increased expression of the coinhibitor 2B4 compared to rejecting patients (p=0.05). To investigate whether 2B4 could confer exhaustion in transplantation, we retrogenically expressed 2B4 on murine CD8+ OT-I T cells (2B4rg) and transferred these cells into naïve recipients prior to giving an OVA-expressing skin graft. We found that 2B4 expression results in significantly reduced accumulation of antigen-specific CD8+ T cells in the spleen 10 days post-transplantation (p=0.03). We observed a marked reduction in the proliferation of CD8+ Thy1.1+ 2B4rg cells when compared to controls as measured by CellTrace Violet (CTV) analysis (p=0.002). The 2B4rg population contained a higher frequency of CTVhi undivided cells compared to the controls, indicating that expression of 2B4 on donor-reactive CD8+ T cells results in reduced recruitment into the response. To investigate the mechanisms by which 2B4 expression results in decreased proliferation, we interrogated differences in the metabolism of 2B4-deficient (2B4KO) T cells. We used the Seahorse extracellular flux assay to determine that 2B4KO cells activated in vitro exhibited increased glycolytic capacity compared to WT controls (p<0.0001). In vivo analysis of 2B4KO vs. WT T cells following infection with Listeria monocytogenes revealed that that 2B4KO T cells show a trend towards increased Glut-1 expression and significantly enhanced uptake of the glucose analog 2-NBDG ex vivo (p=0.02). Thus, we conclude that 2B4 signals serve to inhibit glycolysis, which limits the proliferation and accumulation of alloaggressive CD8+ T cells following transplantation. These data suggest that 2B4 signaling on CD8+ T cells may promote the metabolic shift from resting to effector cell, and raise the possibility that 2B4-mediated manipulation of metabolism may be a novel therapeutic strategy to target the donor-reactive memory T cell responses following transplantation.
CITATION INFORMATION: Laurie S, Liu D, Cortes M, Wagener M, Ford M. 2B4-Mediated Inhibition of Proliferation and Glycolytic Function Attenuates T Cell Alloreactivity. Am J Transplant. 2017;17 (suppl 3).
To cite this abstract in AMA style:Laurie S, Liu D, Cortes M, Wagener M, Ford M. 2B4-Mediated Inhibition of Proliferation and Glycolytic Function Attenuates T Cell Alloreactivity. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/2b4-mediated-inhibition-of-proliferation-and-glycolytic-function-attenuates-t-cell-alloreactivity/. Accessed October 4, 2022.
« Back to 2017 American Transplant Congress